The Number 1 Autoimmune Disorder

Graves’ Hyperthyroidism – The Most Common Autoimmune Disorder in the United States1, 3







Interpreting Hyperthyroidism Can Be Challenging...Through TSH and Subclinical and Clinical Presentation6


“The problem with TSH assays is the interpretation of mildly elevated or slightly decreased levels.” 6



Thyretain Can Quickly Help Differentiate Graves’ Disease Induced ­Autoimmune ­Hyperthyroidism from ­Non-Autoimmune ­Hyperthyroidism




Thyretain TSI Reporter BioAssay is intended for the qualitative detection in serum of thyroid stimulating autoantibodies to the thyroid stimulating hormone (TSH) receptors (TSHRs) on the thyroid. The detection of these stimulating autoantibodies, in conjunction with other clinical and laboratory findings, may be useful as an aid in the differential diagnosis of patients with Graves’ disease (GD).


  1. Jacobson, D., Gange, S., Rose, N., Graham, N. “Epidemiology and Estimated Population Burden of Selected Autoimmune Diseases in the United States.” Clinical Immunology And Immunopathology, Vol. 84 No. 3, p. 223-243.
  2. Godfrey, J. (2004) Toward Optimal Health: The Experts Discuss Thyroid Disfunction. Journal of Women’s Health, Vol. 13 Issue 2, p. 141-146.
  3. Weetman, A.P. “Graves’ Disease.” New England Journal of Medicine, October 2000, 343(17)
  4. Cooper, D. “Hyperthyroidism”. Lancet, 2003, 362:459-68
  5. Thyretain TSI Reporter BioAssay Product Insert
  6. Kaplowitz, P. “Thyroid Testing: When to Worry(not often) and When to Reassure.” Contemporary Pediatrics, January 2007, p. 2.
  7. Andersen, S., Pedersen, KM., Bruun, NH., Laurberg, P. “Narrow Individual Variations in Serum T(4) And T(3) in Normal Subjects: A Clue to the Understanding of Subclinical Thyroid Disease.” J Clin Endrocrinol Metab, March 2002, p. 1068-72.
  8. AACE Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism. Endocrine Practice 2002; 8(6):457-67.
  9. Demers National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines Laboratory Support for the Diagnosis of Thyroid Disease. 2002
  10. Wilson, et al. Subclinical Thyroid Disease. Amer Fam Phys 2005; 72(8); 1517-24.
  11. Desai J. et al. Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors, Annals of Internal Medicine, Vol. 145, p. 660-665.
  12. Ginsberg, J. “Diagnosis and management of Graves’ disease.” Canadian Medical Association Journal, March 2003, 168(5)
  13. Hardman JG, Limbird LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 9th ed. New York, NY: McGraw Hill; 1996:1394.
  14. Braverman LE, Utiger RD, eds. The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2000:515-516,688-689.
  15. Stockwell, J., Grippa, L., Curtiss, T., Jones, A., Kelly, R., Larrimer, A., Lewis, C., Wylie, D., Hata, M., Ewers, S., Houtz, J., Sanders, G., Kohn, L., Li, Y. “Development of a Novel Reporter Cell Line and Standardized Protocol for the Detection of Thyroid Stimulating Immunoglobulin (TSI).